STANDARD BIOTOOLS INC. Cash Flow Statement
LAB|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
STANDARD BIOTOOLS INC. used $43M in operating cash flow and negative free cash flow of $46M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$74.7M | -$190.1M | -$190.1M | -$59.2M | -$64.8M | -$59.0M | -$60.5M | -$76.0M | -$53.3M | -$52.8M | -$16.5M | -$19.0M | -$22.5M | -$16.9M | -$19.1M |
| Depreciation & Amortization | $3.4M | $2.8M | $12.5M | $3.2M | $3.6M | $4.2M | $5.9M | $5.1M | $3.6M | $3.0M | - | - | - | - | - |
| Operating Cash Flow | -$43.3M | -$89.4M | -$89.4M | -$44.1M | -$35.2M | -$25.2M | -$24.1M | -$39.1M | -$34.7M | -$22.6M | -$1.6M | -$17.5M | -$17.5M | -$11.5M | -$19.5M |
| Capital Expenditures | $2.8M | $3.8M | $3.8M | $13.3M | $2.5M | $372.0K | $1.6M | $5.1M | $4.0M | $7.4M | $3.4M | $2.4M | $1.7M | $1.5M | $799.0K |
| Free Cash Flow | -$46.1M | -$93.2M | -$93.2M | -$57.3M | -$37.7M | -$25.6M | -$25.7M | -$44.2M | -$38.7M | -$30.0M | -$5.0M | -$19.9M | -$19.2M | -$13.0M | -$20.3M |
| Share Buybacks | $5.4M | $563.0K | $563.0K | $0 | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | -43.4% | -95.2% | -95.2% | -43.9% | -32.2% | -22.6% | -25.2% | -42.3% | -33.8% | -25.8% | -7.1% | -38.0% | -44.8% | -38.9% | -79.9% |